Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide ...
Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...
The FDA has approved a label expansion for the interleukin-23 inhibitor guselkumab to include the inhibition of structural joint damage progression in adults with psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results